NEW YORK, Sept. 13, 2013 /PRNewswire-iReach/ -- Clinilabs, an early phase and specialty CRO that provides clinical drug development services to industry, announced today the arrival of Dr. Xiang Zhou to the team. Dr. Zhou will be one of the team leaders in Clinilabs' biomarker program, and will be supporting Phase I biomarker trials conducted at the company's Phase I units in NY and NJ.
Dr. Zhou has several years of experience in the field of clinical research and biomarker development. After graduating from the City University of New York (CUNY) he began working in the field of clinical psychiatry at New York University Medical School. During this time, Dr. Zhou contributed to several research projects by designing clinical studies and developing the software to record, analyze, and manage clinical trial data.
While Dr. Zhou's capabilities as a generalist in data management are strong, his primary research focus is on the development of biomarker methods used in the assessment of psychiatric conditions, including depression, schizophrenia, ADHD, and autism using quantitative electroencephalography (QEEG), transcranial electrical stimulation (tDCS) and brain imaging (MRI/fMRI, SPECT/PET). He has published over 10 scholarly articles, and his work has been widely used in both industry and clinical care.
Amy McCoy, Senior Director of Data Services, states "in the past few years, we have seen an increasing demand for the use of biomarkers in clinical trials for the purposes of patient selection or stratification, or to examine pharmacodynamic responses that can assist the decision-making process. Therefore, we are pleased to welcome Dr. Zhou to the Clinilabs team. His education and past work experience will greatly add to our ability to provide outstanding data solutions for Phase I and II studies, and his expertise will contribute to our ability to include biomarker assessments in the studies we conduct for our clients."
About Clinilabs Inc.
Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations. The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide. Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths. Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects. For more information, please visit www.clinilabs.com.
Media Contact: Hannah DAoust, Clinilabs, 646-215-6480, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com